Merck Licenses Cyclica?s In-Silico Artificial Intelligence (AI) based Ligand Express Platform
- Agreement to screen discovery and early development compounds using artificial intelligence and computational biophysics
- Cloud-based in silico platform that screens small molecules to determine polypharmacological profiles
- Evaluation to include identification of potential mechanisms of action for investigational small molecules
Naheed Kurji President and CEO Cyclica Inc naheed.kurji@cyclicarx.com